With €18 million in new international contracts, Gpi closes a record-breaking second quarter in 2025. The value of foreign orders more than doubled compared to the same period last year and increased by 20% over the previous quarter, confirming the strength of the Group’s global strategy.
The Software remains the main driver of growth: thanks to the vertical solutions of the Gpi4Med Suite, new contracts reached €16.5 million. The Gpi4Med.BLOOD suite, dedicated to managing the blood supply chain, accounted for €7.8 million—driven by two major nationwide contracts secured by Gpi Iberia in Wales and Romania, along with €1.3 million in orders from the United States.
Automation also delivered strong results, recording €1.5 million in new contracts. Volume tripled year-on-year and doubled compared to the previous quarter. Iceland, Switzerland, and Saudi Arabia are among the new markets reached, confirming the growing competitiveness of Gpi’s pharmaceutical automation product lines.
The Q2 2025 results strengthen the Group’s global presence and demonstrate its ability to adapt proprietary technologies to diverse contexts. A scalable and sustainable industrial model that continues to generate value across the entire international digital healthcare supply chain.
